MarkWide Research

Sale!

Neuromyelitis Optica Spectrum Disorder Market Analysis- Industry Size, Share, Research Report, Insights, Covid-19 Impact, Statistics, Trends, Growth and Forecast 2022-2030

Published Date: July, 2022
No of Pages: 153
Delivery Format: PDF + Excel

$2,950.00

Market Overview

The Neuromyelitis Optica Spectrum Disorder market is projected to grow with a CAGR of 6% during the forecast period (2022 – 2030).

The COVID-19 pandemic has been continuing to transform the growth of various markets, and the immediate impact of the outbreak is varied. While a few healthcare industries registered a drop in demand, numerous other markets may continue to remain unscathed and show promising growth opportunities. Initially, the global COVID-19 outbreak and the lockdown scenario in various countries have imposed some challenges on the market, as hospitals and clinics were forced to suspend services to prevent the spread of the SARS-CoV-2 virus.

According to an article published by the National Center for Biotechnology Information, in 2021, titled “The impact of COVID-19 pandemic on hospitalizations and plasmapheresis therapy in multiple sclerosis and neuromyelitis optica spectrum disorder: a nationwide analysis from Germany”, during the different pandemic periods in 2020, there was a significant drop in multiple sclerosis and neuromyelitis optica spectrum disorder patient hospitalizations, with the greatest significant reduction occurring during the pandemic’s initial wave. The delayed or interrupted treatment due to the pandemic is thus increasing the risk of relapse in patients. With resumed services and procedures, the hospital visits have increased due to which the demand for treatment will increase, over the forecast period.

The factors propelling the growth of the market are the increasing incidence and prevalence of neuromyelitis optica spectrum disorder (NMOSD), increasing research and development activities, product approvals, and rising demand for better treatment options for neuromyelitis optica spectrum disorder patients. For instance, according to an article published by Neurology, in 2021, titled “Worldwide Incidence and Prevalence of Neuromyelitis Optica: A Systematic Review”, the findings revealed that the incidence and prevalence rate of neuromyelitis optica spectrum disorder was highest in the Afro-Caribbean area and lowest in Australia and New Zealand areas.

Furthermore, the increasing research and development activities and product approvals by the companies are also contributing to the growth of the market. For instance, in August 2020, Chugai Pharmaceuticals launched Enspryng Subcutaneous Injection for the prevention of relapses of neuromyelitis optica spectrum disorder (NMOSD) including neuromyelitis Optica (NMO). Similarly, In June 2020, The United States Food and Drug Administration (FDA) approved Viela Bio’s UPLINZA, for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD).

Neuromyelitis Optica Spectrum Disorder Market  Report Scope and Segmentation

ATTRIBUTESDETAILS
ESTIMATED YEAR2022
BASE YEAR2021
FORECAST YEAR2030
HISTORICAL YEAR2017-2021
UNITValue (USD Million/Billion)
BY REGIONNorth America, Europe, Asia Pacific, Latin America, Middle East and Africa

Scope of the Report

As per the scope of the report, Neuromyelitis Optica Spectrum Disorder is an autoimmune disorder in which white blood cells and antibodies attack and damage the optic nerve, resulting in discomfort and visual loss, spinal cord causing paralysis, loss of sensation in the legs and arms, and problems with bladder and bowel function. The Global Neuromyelitis Optica Spectrum Disorder Market is segmented by Treatment (Immunosuppressive Agents, Plasma Exchange Therapy, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, South America). The report offers the value (in USD million) for the above segments.

Treatment Type

  • Medication
  • Immunosuppressive Agent
  • C5 Protein Inhibitor
  • Monoclonal Antibodies
  • Corticosteroids
  • Others
  • Plasma Exchange Therapy
  • Immunoglobulin Therapy
  • Diagnosis
  • Imaging Tests
  • Magnetic resonance imaging (MRI)
  • Others
  • Blood Tests
  • Others

Dosage form

  • Tablets
  • Injections
  • Others

Route of Administration

  • Oral
  • Parenteral
  • Others

End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Key Market Trends

Monoclonal Antibody Drugs Segment Expects to Register a High CAGR in the Forecast Period

The monoclonal antibody drugs segment is expected to hold the largest share in this market segment. It is considered an emerging therapy as well as a better option for autoimmune diseases including neuromyelitis optica spectrum disorder due to its high efficacy and tolerability. B cells play a pathogenic role by producing auto-antibodies, secretion of cytokines/chemokines, and antigen presentation-T cell interactions in neuromyelitis optica spectrum disorder. As a result, monoclonal antibody-mediated B cell depletion has become a treatment option for neuromyelitis optica spectrum disorder (NMOSD). Some of the monoclonal antibody drugs used for the treatment of NMOSD include Rituximab, Inebilizumab, Tocilizumab, Satralizumab, and Eculizumab.

The increasing monoclonal anti-body drug approvals and rising research and development activities by the players for developing effective treatment options for patients with neuromyelitis optica spectrum disorder are also increasing the market growth. For instance, in November 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), granted a market authorization to Horizon’s UPLINZA, as a monotherapy, for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who tested positive for anti-aquaporin-4 immunoglobulin G ( (AQP4-IgG+) antibodies.

Thus, the increasing efficacy and tolerability of monoclonal antibody drugs, rising product approvals, and research and development activities by the market players are propelling the growth of the segment which further increases the market growth over the forecast period.

North America is Expected to Have the Significant Market Share

North America is witnessed to have a large market share owing to the factors such as the increasing incidence and prevalence of neuromyelitis optica spectrum disorder, well-established healthcare infrastructure, and the availability of efficient treatment methods.

The increasing incidences of neuromyelitis optica spectrum disorder is the key factor driving the growth of the market over the forecast period. According to an article published by the National Center for Biotechnology Information, in 2021, titled “Identification and temporal trends of patients with neuromyelitis optica spectrum disorder in a US insurance claims database”, neuromyelitis optica spectrum disorder affects about 15,000 people in the United States.

In addition, the increasing company’s research and development activities and non-profit organizations’ financial assistance programs for people with neuromyelitis optica spectrum disorder are also contributing to the growth of the market in the region. For instance, in November 2021, The Patient Access Network (PAN) Foundation opened a new financial assistance program for people living with neuromyelitis optica spectrum disorder.

Furthermore, the increasing product approvals in the region are also contributing to the growth of the market over the forecast period. For instance, in August 2020, the United States Food and Drug Administration (FDA) approved Genetech’s Enspryng (satralizumab-mwge), for the treatment of adult patients, with neuromyelitis optica spectrum disorder (NMOSD), who are anti-aquaporin-4 or AQP4 antibody-positive.

Thus, the increasing prevalence of neuromyelitis optica spectrum disorder, rising research and development activities as well as increasing product approvals are likely to increase the market growth in the near future.

Competitive Landscape

The neuromyelitis optica spectrum disorder market is moderatively competitive with the presence of a large number of players in the market. The companies are focusing on adopting various business strategies such as collaboration, acquisitions, and product approval to withhold the market position. Some of the key players are Hoffmann-La Roche Ltd, Horizon Therapeutics plc, TG Therapeutics, Opexa Therapeutics, and Mitsubishi Tanabe Pharma.

Major Players

  1. Hoffmann-La Roche Ltd
  2. TG Therapeutics
  3. Opexa Therapeutics
  4. Mitsubishi Tanabe Pharma
  5. Horizon Therapeutics plc (Viela Bio)
  6. CHUGAI PHARMACEUTICAL/ ROCHE
  7. ALEXION PHARMA
  8. Others

Regional Analysis

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • Italy
    • France
    • UK
    • Spain
    • Poland
    • Russia
    • The Netherlands
    • Norway
    • Czech Republic
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Indonesia
    • Malaysia
    • Thailand
    • Singapore
    • Australia & New Zealand
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Rest of South America
  • The Middle East & Africa
    • Saudi Arabia
    • UAE
    • South Africa
    • Northern Africa
    • Rest of MEA

Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Neuromyelitis Optica Spectrum Disorder NMOSD Market Overview    4.1 Introduction       4.1.1 Market Taxonomy       4.1.2 Market Definition       4.1.3 Macro-Economic Factors Impacting the Market Growth    4.2 Neuromyelitis Optica Spectrum Disorder NMOSD Market Dynamics       4.2.1 Market Drivers       4.2.2 Market Restraints       4.2.3 Market Opportunity    4.3 Neuromyelitis Optica Spectrum Disorder NMOSD Market – Supply Chain Analysis       4.3.1 List of Key Suppliers       4.3.2 List of Key Distributors       4.3.3 List of Key Consumers    4.4 Key Forces Shaping the Neuromyelitis Optica Spectrum Disorder NMOSD Market       4.4.1 Bargaining Power of Suppliers       4.4.2 Bargaining Power of Buyers       4.4.3 Threat of Substitution       4.4.4 Threat of New Entrants       4.4.5 Competitive Rivalry    4.5 Global Neuromyelitis Optica Spectrum Disorder NMOSD Market Size & Forecast, 2018-2028       4.5.1 Neuromyelitis Optica Spectrum Disorder NMOSD Market Size and Y-o-Y Growth       4.5.2 Neuromyelitis Optica Spectrum Disorder NMOSD Market Absolute $ Opportunity

Chapter 5 Global Neuromyelitis Optica Spectrum Disorder NMOSD Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Neuromyelitis Optica Spectrum Disorder NMOSD Market Size Forecast by Type
5.2.1 Intravenous
5.2.2 Oral
5.2.3 Subcutaneous
5.2.4 Others
5.3 Market Attractiveness Analysis by Type

Chapter 6 Global Neuromyelitis Optica Spectrum Disorder NMOSD Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Neuromyelitis Optica Spectrum Disorder NMOSD Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications

Chapter 7 Global Neuromyelitis Optica Spectrum Disorder NMOSD Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Neuromyelitis Optica Spectrum Disorder NMOSD Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region

Chapter 8 Coronavirus Disease (COVID-19) Impact 
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario

Chapter 9 North America Neuromyelitis Optica Spectrum Disorder NMOSD Analysis and Forecast
9.1 Introduction
9.2 North America Neuromyelitis Optica Spectrum Disorder NMOSD Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Neuromyelitis Optica Spectrum Disorder NMOSD Market Size Forecast by Type
9.6.1 Intravenous
9.6.2 Oral
9.6.3 Subcutaneous
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Neuromyelitis Optica Spectrum Disorder NMOSD Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications

Chapter 10 Europe Neuromyelitis Optica Spectrum Disorder NMOSD Analysis and Forecast
10.1 Introduction
10.2 Europe Neuromyelitis Optica Spectrum Disorder NMOSD Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Neuromyelitis Optica Spectrum Disorder NMOSD Market Size Forecast by Type
10.6.1 Intravenous
10.6.2 Oral
10.6.3 Subcutaneous
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Neuromyelitis Optica Spectrum Disorder NMOSD Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications

Chapter 11 Asia Pacific Neuromyelitis Optica Spectrum Disorder NMOSD Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Neuromyelitis Optica Spectrum Disorder NMOSD Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Neuromyelitis Optica Spectrum Disorder NMOSD Market Size Forecast by Type
11.6.1 Intravenous
11.6.2 Oral
11.6.3 Subcutaneous
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Neuromyelitis Optica Spectrum Disorder NMOSD Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications

Chapter 12 Latin America Neuromyelitis Optica Spectrum Disorder NMOSD Analysis and Forecast
12.1 Introduction
12.2 Latin America Neuromyelitis Optica Spectrum Disorder NMOSD Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Neuromyelitis Optica Spectrum Disorder NMOSD Market Size Forecast by Type
12.6.1 Intravenous
12.6.2 Oral
12.6.3 Subcutaneous
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Neuromyelitis Optica Spectrum Disorder NMOSD Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications

Chapter 13 Middle East & Africa (MEA) Neuromyelitis Optica Spectrum Disorder NMOSD Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Neuromyelitis Optica Spectrum Disorder NMOSD Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Neuromyelitis Optica Spectrum Disorder NMOSD Market Size Forecast by Type
13.6.1 Intravenous
13.6.2 Oral
13.6.3 Subcutaneous
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Neuromyelitis Optica Spectrum Disorder NMOSD Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications

Chapter 14 Competition Landscape 
14.1 Neuromyelitis Optica Spectrum Disorder NMOSD Market: Competitive Dashboard
14.2 Global Neuromyelitis Optica Spectrum Disorder NMOSD Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 F. Hoffmann-La Roche Ltd
14.3.2 Alexion Pharmaceuticals
14.3.3 RemeGen
14.3.4 Nihon Pharmaceutical
14.3.5 Harbour BioMed
14.3.6 Lundbeck
14.3.7 Bionure
14.3.8 Opexa Therapeutics
14.3.9 TG Therapeutics
14.3.10 Bio-Thera Solutions
14.3.11 Boston Pharmaceuticals
14.3.12 Cour Pharmaceutical

Treatment Type

  • Medication
  • Immunosuppressive Agent
  • C5 Protein Inhibitor
  • Monoclonal Antibodies
  • Corticosteroids
  • Others
  • Plasma Exchange Therapy
  • Immunoglobulin Therapy
  • Diagnosis
  • Imaging Tests
  • Magnetic resonance imaging (MRI)
  • Others
  • Blood Tests
  • Others

Dosage form

  • Tablets
  • Injections
  • Others

Route of Administration

  • Oral
  • Parenteral
  • Others

End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others
  1. Hoffmann-La Roche Ltd
  2. TG Therapeutics
  3. Opexa Therapeutics
  4. Mitsubishi Tanabe Pharma
  5. Horizon Therapeutics plc (Viela Bio)
  6. CHUGAI PHARMACEUTICAL/ ROCHE
  7. ALEXION PHARMA
  8. Others

Why Choose MWR

Quality Research

Our goal is to provide high-quality data that stimulates growth and creates a win-win situations

Unlimited User Access 

We offer Corporate User license access on all our reports in which you can share the report with your entire team without any restrictions

Free Company Inclusion 

We give you an option to include 3-4 additional company players of your choice in our report without any extra charges

Post Sale Assistance

Unlimited post sales service with an account manager dedicated to making sure that all your needs are met

Covid-19 Impact Analysis

All our research report includes latest Covid-19 Impact and its analysis

Download Free Sample PDF

444 Alaska Avenue

Suite #BAA205 Torrance, CA 90503 USA

+1 424 360 2221

24/7 Customer Support

Download Free Sample PDF